Ruixin Medical and Bluetech Medical Announce Strategic Partnership to Globalize AI-Powered Coronary Physiology and Microcirculation Assessment Technology

May 17, 2026 22:32 CST Updated 22:32

RaysightMed

Medical Imaging Product Developer

Recently, Shenzhen Raysightmed Co, Ltd. ("RaysightMed") and Beijing Lanfan Baisheng Medical Technology Co., Ltd. ("Lanfan Baisheng"), the operating entity of Blausen’s Cardio-Cerebrovascular Division, officially signed a strategic cooperation agreement. Grounded in the global market, both parties will leverage their core strengths in technology development and commercialization to promote the domestic and overseas implementation of RaysightMed's self-developed AngioQFA one-stop coronary FFR\IMR evaluation system. This collaboration aims to empower global coronary intervention diagnosis and treatment with AI innovative technologies and support China-manufactured medical products in reaching the world.

Deepening Technological Innovation, Establishing a New Benchmark for Coronary "Functional + Microcirculation" Assessment

Currently, the diagnosis and treatment of coronary heart disease have moved from simple anatomical assessment to a new stage of comprehensive evaluation of "epicardial + microvascular dysfunction." The 2024 European Society of Cardiology (ESC) guidelines for the management of chronic coronary syndrome explicitly list the assessment of microvascular dysfunction as a key component in the diagnosis and treatment of coronary heart disease.

Among them, the Fractional Flow Reserve (FFR) is the gold standard for evaluating ischemia caused by epicardial coronary artery stenosis, while the Index of Microcirculatory Resistance (IMR) is the core indicator for assessing microvascular function. Both are crucial for clinical diagnosis and treatment decisions.

RaysightMed, as an innovative leader in the field of cardiovascular precision diagnosis and treatment, independently developedAngioQFA One-Stop Coronary FFR\IMR Assessment System, is a globally leading integrated platform for assessing coronary functional performance. The system deeply integrates artificial intelligence with computational fluid dynamics technology, based on routine coronary angiography images,Simulation calculation can be completed in 10 seconds, and the full-process report can be output in 3-5 minutes.，One examination simultaneously obtains two core indicators, FFR and IMR, achieving an efficient diagnosis and treatment model of "one scan, dual assessment."

Compared with the traditional pressure wire measurement method, AngioQFA has three disruptive advantages:

Non-invasive and safe, reducing diagnostic and therapeutic risks: No interventional operation required, no vascular damage, no need for vasodilator drugs such as adenosine, effectively avoiding contraindications and adverse reactions. It is also equipped with the first Bluetooth pressure sensor, supporting operations outside the catheter room, reducing radiation exposure for both doctors and patients.
Precise and Reliable, Outstanding Clinical Value: Prospective multicenter clinical trials validated that, compared with the gold standard of guidewires, the system demonstrated high accuracy, sensitivity, and specificity in FFR and IMR assessments.Up to 95%The above provides precise basis for clinical decision-making.
Comprehensive and Efficient, Adaptable to Diverse Scenarios: Supports 3D reconstruction of multiple vascular structures, capable of stitching up to 4 angiographic images for cross-sequence reconstruction, compatible with single/multi-image analysis modes, meeting the needs for both simple and complex lesion evaluations, significantly improving diagnostic and treatment efficiency.

Currently, AngioQFA has been successfully approved.National Medical Products Administration Class III Medical Device Registration Certificate (Registration No. 20243072626), and has been included in the national medical insurance fee support system, laying a policy foundation for clinical popularization in China.

From a global market perspective, the penetration rate of FFR guidewires is relatively high in mature markets such as Europe, the United States, Japan, and South Korea. AngioQFA, innovatively launched by RaysightMed globally, offers advantages such as being non-invasive, simple, and highly precise, providing significant room for substitution and offering tremendous opportunities for overseas expansion of the product. Meanwhile, the penetration rate in China and most emerging markets remains extremely low, indicating vast market potential to provide patients with high-quality, non-invasive, and precise diagnostic services.

Powerful Collaboration for Win-Win Results, Accelerating the Global Layout of China's Innovative Technologies

This strategic cooperation is an important milestone in RaysightMed's global strategy, and also a strong collaboration between domestically innovated medical devices and a global commercial platform.

Beijing Lanfan Baisheng Medical Technology Co., Ltd. has been deeply engaged in the field of cardiovascular and cerebrovascular interventions for many years, establishing a global self-commercialization system covering coronary interventions and structural heart diseases. It possesses comprehensive capabilities across the entire process of R&D, clinical trials, production, registration, and sales. The company has set up localized market teams with hundreds of members in the APAC and EMEIA regions, while its channels in China cover medical institutions at all levels. It boasts top-tier academic promotion and clinical service capabilities and has successfully supported multiple innovative Chinese medical device companies in achieving global implementation, demonstrating strong commercialization capabilities.

According to the agreement, Lanfan Baisheng will leverage its global registration and sales network advantages to assist in the certification and market entry of the AngioQFA system in key overseas regions, while initiating a distribution partnership. This collaboration will effectively address RaysightMed's limitations in overseas commercial channels, rapidly advancing the global market application of the product. Meanwhile, the introduction of AngioQFA will enhance Lanfan Baisheng’s comprehensive coronary intervention solutions, achieving strong synergy between both parties’ products and technologies, and jointly exploring new growth opportunities in the global market.

Sticking to the Original Aspiration of Innovation, Aiding High-Quality Development in Global Cardiovascular Diagnosis and Treatment

RaysightMed always adheres to"Using Intelligent Technology, Safeguarding the Longer Rhythm of Life"The mission focuses on the field of cardiovascular precision diagnosis and treatment, with core technologies such as AI, 3D simulation, and robotics, continuously addressing clinical pain points. From the AngioQFA one-stop functional assessment system, to the fully automatic AI vascular interventional surgery robot, to the Ruixin-FFR postoperative evaluation system, the company has established a comprehensive cardiovascular intelligent diagnosis and treatment solution covering the entire process of "diagnosis-treatment-postoperative management," promoting the advancement of coronary heart disease diagnosis and treatment towards precision, intelligence, and efficiency.

In the future, RaysightMed will take this strategic cooperation as an opportunity to continue to focus on technological innovation, iterate and optimize product performance, and expand clinical application scenarios. At the same time, joining hands with Lanfan Baisheng, it will accelerate the global implementation of the AngioQFA system, allowing China's original AI medical technology to benefit more cardiovascular disease patients worldwide. RaysightMed will also continue to adhere to its original intention of medical innovation, strengthen industrial collaboration at home and abroad, promote China's high-end medical devices from "China production substitution" to "global leadership," and help elevate the level of global cardiovascular interventional diagnosis and treatment to new heights.